Skip to menu Skip to content Skip to footer

2013

Conference Publication

Micrornas as novel anti-angiogenesis therapeutic targets

Plummer, Prue N., Balsara, Spenta, Umer, Brittany, Taft, Ryan, Ferro, Vito, Mattick, John S., Swarbrick, Alex, McMillan, Nigel, Mittal, Vivek and Mellick, Albert S. (2013). Micrornas as novel anti-angiogenesis therapeutic targets. 8th Meeting of the Australasian GeneTherapy-Society, Sydney, NSW Australia, 08-10 May 2013. Hoboken, NJ United States: John Wiley and Sons Inc.. doi: 10.1002/jgm.2740

Micrornas as novel anti-angiogenesis therapeutic targets

2013

Conference Publication

Nanoparticle Delivery of Rna-Based Therapy to Modulate Tumour Vasculature: as a Next Generation Anticancer Therapy

Plummer, Prue N., Balsara, Spenta, Ferro, Vito, Mittal, Vivek and Mellick, Albert S. (2013). Nanoparticle Delivery of Rna-Based Therapy to Modulate Tumour Vasculature: as a Next Generation Anticancer Therapy. 8th Meeting of the Australasian-Gene-Therapy-Society, Sydney Australia, 08-10 May 2013. Hoboken, NJ United States: Jossey Bass, Ed. and Pub.. doi: 10.1002/jgm.2740

Nanoparticle Delivery of Rna-Based Therapy to Modulate Tumour Vasculature: as a Next Generation Anticancer Therapy

2007

Conference Publication

Heparan sulfate mimetics - potent angiogenesis inhibitors for cancer therapy

Dredge, K, Davis, K, Liu, L, Johnstone, K, Handley, P, Wimmer, N, Bytheway, I, Hammond, E, Li, CP, Rowley, J, Ferro, V and Gautam, A (2007). Heparan sulfate mimetics - potent angiogenesis inhibitors for cancer therapy. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, United States, 22-26 October 2007. Philadelphia, PA, United States: American Association for Cancer Research.

Heparan sulfate mimetics - potent angiogenesis inhibitors for cancer therapy

2005

Conference Publication

PI-88, a heparanase inhibitor showing promising evidence of patient benefit in phase II clinical trials.

Gautam, AM, Ferro, V, Wilson, EA, Freeman, C and Parish, C (2005). PI-88, a heparanase inhibitor showing promising evidence of patient benefit in phase II clinical trials.. AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia Pa, Nov 14-18, 2005. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.

PI-88, a heparanase inhibitor showing promising evidence of patient benefit in phase II clinical trials.

2001

Conference Publication

Pharmacokinetics of [35s] PI-88 in rats

Creese, B., Ferro, V., King, A. R., Mardon, K. M., Dickinson, R. G., Punler, M.J. and Dodds, H. (2001). Pharmacokinetics of [35s] PI-88 in rats. Annual Scientific Meeting of ASCEPT, Dunedin NZ, 3-5 December 2001. Melbourne: ASCEPT.

Pharmacokinetics of [35s] PI-88 in rats